Incidence of severe urinary tract infections not increased by initiating sodium-glucose cotransporter 2 inhibitors

Affiliations

Review

Hiroki Yokoyama. J Diabetes Investig. 2020 May.

. 2020 May;11(3):530-531.

doi: 10.1111/jdi.13189. Epub 2020 Jan 7.

No abstract available

Conflict of interest statement

The author declares no conflict of interest.

1. U.S. Food and Drug Administration. FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tractinfections. Updated 19 January 2018. Available from: www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐drug‐safety‐communica... Accessed June 15 2019.
1. Wu JH, Foote C, Blomster J, et al Effects of sodium‐glucose cotransporter‐2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta‐analysis. Lancet Diabetes Endocrinol 2016; 4: 411–419. - PubMed
1. Dave CV, Schneeweiss S, Kim D, et al Sodium‐glucose cotransporter‐2 inhibitors and the risk for severe urinary tract infections: a population‐based cohort study. Ann Intern Med 2019; 171: 248–256. - PMC - PubMed
1. Yokoyama H, Nagao A, Watanabe S, et al Incidence and risk of vaginal candidiasis associated with sodium‐glucose cotransporter 2 inhibitors in real‐world practice for women with type 2 diabetes. J Diabetes Investig 2019; 10: 439–445. - PMC - PubMed
1. Zhanel GG, Nicolle LE, Harding GK. Manitoba Diabetic Urinary Infection Study Group. Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus. Clin Infect Dis 1995; 21: 316–322. - PubMed